RRM2 is a Potential Prognostic Biomarker with Functional Significance in Glioma

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2019 Feb 13

PMID 30745840

Citations 36

Authors

Hongzhi Sun

Bingya Yang

Hao Zhang

Jingwei Song

Yenan Zhang

Jicheng Xing

Zhihui Yang

Changyong Wei

Tuoye Xu

Zhennan Yu

Zhipeng Xu

Min Hou

Minjun Ji

Yansong Zhang

Affiliations

Soon will be listed here.

Abstract

Glioma is one of the most common brain tumors, suggesting the importance of investigating the molecular mechanism of gliomas. We studied the roles of Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in glioma. Expressions of RRM2 are higher in glioma tissues evidenced by TCGA data, western blot and immunohistochemistry. RRM2 is negatively correlated with glioma patient's survival. RNA-seq showed that genes involved in apoptosis, proliferation, cell adhesion and negative regulation of signaling were up-regulated upon RNAi-mediated knock-down of RRM2. Cell phenotypes specific for stably knocking down RRM2 were determined using stable transfection . In an model, knock-down of RRM2 inhibited tumor growth and caused suppression of AKT and ERK1/2 signalings. Interfering RRM2 also down-regulated the expression of cyclin A, cyclin B1, cyclin D1, Vimentin, and N-cadherin, and elevated E-cadherin expression. Moreover, overexpression of RRM2 failed to increase the expression of cyclin B1, cyclin D1, and N-cadherin when phosphorylation of AKT and ERK1/2 was suppressed by LY294002 or PD98059. These findings indicated that RRM2 is a positive regulator of glioma progression which contributes to the migration and proliferation of glioma cells through ERK1/2 and AKT signalings and might be a novel prognostic indicator for glioma patients.

Citing Articles

Decoding the immune microenvironment: unveiling CD8 + T cell-related biomarkers and developing a prognostic signature for personalized glioma treatment.

Lin X, Liu J, Zhang N, Zhou D, Liu Y Cancer Cell Int. 2024; 24(1):331.

PMID: 39354483 PMC: 11443942. DOI: 10.1186/s12935-024-03517-9.

Identification of the ferroptosis-related gene signature and the associated regulation axis in lung cancer and rheumatoid arthritis.

Cai B, Huang Y, Liu D, You Y, Chen N, Jie L Genes Immun. 2024; 25(5):367-380.

PMID: 39080453 DOI: 10.1038/s41435-024-00287-2.

A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer.

Wang Y, Chen R, Zhang J, Zeng P PLoS One. 2024; 19(4):e0299949.

PMID: 38635758 PMC: 11025932. DOI: 10.1371/journal.pone.0299949.

RRM2 promotes the proliferation of chicken myoblasts, inhibits their differentiation and muscle regeneration.

Chen B, Zhang Y, Niu Y, Wang Y, Liu Y, Ji H Poult Sci. 2024; 103(3):103407.

PMID: 38198913 PMC: 10825555. DOI: 10.1016/j.psj.2023.103407.

Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor.

Giang L, Wu K, Lee W, Chu S, Do A, Changou C J Exp Clin Cancer Res. 2023; 42(1):346.

PMID: 38124207 PMC: 10731702. DOI: 10.1186/s13046-023-02911-x.

References

Cloughesy T, Cavenee W, Mischel P . Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2013; 9:1-25. DOI: 10.1146/annurev-pathol-011110-130324. View

Jiang T, Zhao B, Li X, Wan J . ARPP-19 promotes proliferation and metastasis of human glioma. Neuroreport. 2016; 27(13):960-6. DOI: 10.1097/WNR.0000000000000638. View

Vehlow A, Cordes N . Invasion as target for therapy of glioblastoma multiforme. Biochim Biophys Acta. 2013; 1836(2):236-44. DOI: 10.1016/j.bbcan.2013.07.001. View

Chautard E, Ouedraogo Z, Biau J, Verrelle P . Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness. J Neurooncol. 2014; 117(2):205-15. DOI: 10.1007/s11060-014-1382-9. View

Chen S, Zhou Y, Chen Y, Gu J . fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018; 34(17):i884-i890. PMC: 6129281. DOI: 10.1093/bioinformatics/bty560. View

Mure H, Matsuzaki K, Kitazato K, Mizobuchi Y, Kuwayama K, Kageji T . Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol. 2010; 12(3):221-32. PMC: 2940586. DOI: 10.1093/neuonc/nop026. View

Yoshida Y, Tsunoda T, Doi K, Tanaka Y, Fujimoto T, Machida T . KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines. Anticancer Res. 2011; 31(7):2535-9. View

Zhao H, Zhang H, Du Y, Gu X . Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2014; 35(12):12679-88. DOI: 10.1007/s13277-014-2592-7. View

Tang H, Xiao G, Behrens C, Schiller J, Allen J, Chow C . A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res. 2013; 19(6):1577-86. PMC: 3619002. DOI: 10.1158/1078-0432.CCR-12-2321. View

10.

Pan Y, Zhang Y, Chen L, Liu Y, Feng Y, Yan J . The Critical Role of Rab31 in Cell Proliferation and Apoptosis in Cancer Progression. Mol Neurobiol. 2015; 53(7):4431-7. DOI: 10.1007/s12035-015-9378-9. View

11.

Wang L, Meng L, Wang X, Ma G, Chen J . Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2013; 35(3):1899-906. DOI: 10.1007/s13277-013-1255-4. View

12.

Tanaka S, Louis D, Curry W, Batchelor T, Dietrich J . Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nat Rev Clin Oncol. 2012; 10(1):14-26. DOI: 10.1038/nrclinonc.2012.204. View

13.

Su Y, Wu T, Ko J, Tsai H, Tee Y, Chien M . The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. PLoS One. 2014; 9(3):e91644. PMC: 3956764. DOI: 10.1371/journal.pone.0091644. View

14.

Zhang H, Liu X, Warden C, Huang Y, Loera S, Xue L . Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers. BMC Cancer. 2014; 14:664. PMC: 4171582. DOI: 10.1186/1471-2407-14-664. View

15.

Rahman M, Amin A, Wang D, Koenig L, Nannapaneni S, Chen Z . RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clin Cancer Res. 2013; 19(13):3416-28. PMC: 3747783. DOI: 10.1158/1078-0432.CCR-13-0073. View

16.

Zheng K, Wang G, Li C, Shan X, Liu H . Knockdown of ILK inhibits glioma development via upregulation of E-cadherin and downregulation of cyclin D1. Oncol Rep. 2015; 34(1):272-8. DOI: 10.3892/or.2015.3983. View

17.

Wu A, Wu B, Guo J, Luo W, Wu D, Yang H . Elevated expression of CDK4 in lung cancer. J Transl Med. 2011; 9:38. PMC: 3094221. DOI: 10.1186/1479-5876-9-38. View

18.

Jiang T, Tang G, Lin Y, Peng X, Zhang X, Zhai X . Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study. Chin Med J (Engl). 2011; 124(17):2578-83. View

19.

Kopylova E, Noe L, Touzet H . SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics. 2012; 28(24):3211-7. DOI: 10.1093/bioinformatics/bts611. View

20.

Ostrom Q, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. Neuro Oncol. 2017; 18(suppl_5):v1-v75. PMC: 8483569. DOI: 10.1093/neuonc/now207. View